Advances in ADT: Part II: A Guide for APPs (2023)

September 26, 2023

COMPLIMENTARY CME VIRTUAL COURSE!

September 26, 2023 | Time: 7:00-8:00 PM EDT


Based on the documented need from the AUA Advanced Prostate Cancer Global Needs Assessment, the AUA has created Advances in ADT: Part II: A Guide for APPs (2023), an educational offering to further update APPs on the latest advancements in androgen deprivation therapy (ADT) and prostate cancer treatment. This educational initiative is comprised of multiple formats, including a live course and on-demand webcast. This live virtual course, which is the cornerstone of the initiative features a multidisciplinary panel, engaging in a lively discussion. 


ACKNOWLEDGEMENT

Independent educational grant support provided by:

  • Myovant Sciences LTD
  • Pfizer Inc.

Target Audience

  • APPs

Learning Objectives

At the conclusion of ADT Part II: A Guide for APPs, participants will be able to:

  1. Recognize the need for a multidisciplinary team to provide care for patients with advanced prostate cancer.
  2. Classify stages of advanced prostate cancer based on clinical and radiographic modalities.
  3. Apply treatment strategies for different stages of advanced prostate cancer based on current guidelines.
  4. Evaluate and manage comorbid conditions for patients with advanced prostate cancer on systemic therapies.
  5. Describe the role of genetic testing to guide therapies for patients with advanced prostate cancer.
  6. Assess treatment barriers and access to care to therapies for advanced prostate cancer.
Course summary
Available credit: 
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Non-Physician Participation
Course opens: 
07/17/2023
Course expires: 
09/26/2026
Event starts: 
09/26/2023 - 7:00pm EDT
Event ends: 
09/26/2023 - 8:00pm EDT
Rating: 
0

Welcome and Introductions

Pre-test

Segment 1: Biochemical recurrence without metastasis

Segment 2: Metastatic castration sensitive prostate cancer

Segment 3: Non-metastatic castration resistant prostate cancer  

Segment 4: Metastatic castration resistant prostate cancer

Post-test

Questions and Answers

Wrap-u

***Instructions***

  1. Click on the TAKE COURSE button.
  2. Click “Start” under "Live Virtual Course" in the Course Progress pane.
  3. Click on the link provided to register in advance for this live virtual course.
  4. After registering, you will receive a confirmation email containing information about joining the live virtual course. 

Education Council Disclosures

PDF iconEducation Council Disclosures

COI Review Work Group Disclosures

PDF iconCOI Review Work Group Disclosures_2023.pdf


AUA Office of Education Staff has nothing to disclose.

All relevant financial relationships have been mitigated.

Course Director(s)

Rachel Hastings, PA-C, MS

has no relevant financial relationships to disclose at this time.
Faculty(s)

Rana Mckay, MD

has a financial relationship (Consultant or Advisor (General Urology)) with Janssen;.
has a financial relationship (Consultant or Advisor (Oncology)) with Calithera;.
has a financial relationship (Consultant or Advisor (Oncology)) with Pfizer;.
has a financial relationship (Consultant or Advisor (Oncology)) with Dendreon;.
has a financial relationship (Consultant or Advisor (Oncology)) with Exelixis;.
has a financial relationship (Scientific Study or Trial (Oncology)) with Aveo;.
has a financial relationship (Consultant or Advisor (Oncology)) with Sanofi;.
has a financial relationship (Scientific Study or Trial (Oncology)) with Lilly;.
has a financial relationship (Consultant or Advisor (General Urology)) with Novartis ;.
has a financial relationship (Consultant or Advisor (Non-urology Healthcare Related)) with Tempus ;.
has a financial relationship (Consultant or Advisor (Oncology)) with SeaGen;.
has a financial relationship (Consultant or Advisor (Oncology)) with Myovant;.
has a financial relationship (Scientific Study or Trial (Oncology)) with AstraZeneca ;.
has a financial relationship (Consultant or Advisor (Non-urology Healthcare Related)) with BMS;.
has a financial relationship (Consultant or Advisor (Oncology)) with Telix;.
has a financial relationship (Consultant or Advisor (Oncology)) with Merck;.
has a financial relationship (Consultant or Advisor (Oncology)) with caris;.
has a financial relationship (Scientific Study or Trial (Non-urology Healthcare Related)) with Bayer ;.

Doris Salazar, NP

has no relevant financial relationships to disclose at this time.

ACCREDITATION: 

The American Urological Association (AUA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

CREDIT DESIGNATION: 

The American Urological Association designates this live activity for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

OTHER LEARNERS: 

The AUA is not accredited to offer credit to participants who are not MDs or DOs. However, the AUA will issue documentation of participation that states that the activity was certified for AMA PRA Category 1 Credit™.

EVIDENCE BASED CONTENT: 

It is the policy of the AUA to ensure that the content contained in this CME activity is valid, fair, balanced, scientifically rigorous, and free of commercial bias.

AUA DISCLOSURE POLICY: 

All persons in a position to control the content of an educational activity (i.e., activity planners, presenters, authors) are required to disclose to the provider all financial relationships with any commercial interest (aka ineligible company) during the previous 24 months. The AUA must determine if the individual’s relationships may influence the educational content and mitigate any conflicts of interest prior to the commencement of the educational activity. The intent of this disclosure is not to prevent individuals with relevant financial relationships from participating, but rather to provide learners information with which they can make their own judgments.

MITIGATION OF IDENTIFIED CONFLICT OF INTEREST: 

All disclosures will be reviewed by the AUA Conflict of Interest (COI) Review Work Group Chair and/or Vice Chair for identification of conflicts of interest. The AUA COI Review Work Group, working with Office of Education staff, will document the mechanism(s) for management and mitigation of the conflict of interest and final approval of the activity will be documented prior to implementation. Any of the mechanisms below can/will be used to mitigate conflict of interest:

  • Peer review for valid, evidence-based content by the AUA COI Review Work Group.
  • Attestation that clinical recommendations are evidence-based and free of commercial bias.
  • Introduction of a debate format (point-counterpoint)
  • Inclusion of moderated panel discussion with unbiased moderator
  • Publication of a parallel or rebuttal article for an article that is felt to be biased
  • Divestiture of the relationship by faculty
  • Recusal from controlling relevant aspects of planning
  • Selection of alternative faculty for specific topic

OFF-LABEL OR UNAPPROVED USE OF DRUGS OR DEVICES: 

The audience is advised that this continuing medical education activity may contain reference(s) to off-label or unapproved uses of drugs or devices. Please consult the prescribing information for full disclosure of approved uses.

Available Credit

  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Non-Physician Participation
Please login or register to take this course.

Registration for Advances in ADT: Part II: A Guide for APPs (2023) is complimentary.

To join the live virtual course:

  1. Click on the TAKE COURSE button.
  2. Click “Live Virtual Course” in the Course Progress pane.
  3. Click the link to register in advance.
  4. After registering, you will receive a confirmation email containing information about joining the live virtual course.

Attendee Information & Policies

AUA Anti-Harassment Policy

AUA Commitment: AUA is committed to providing a safe and productive meeting environment that fosters open dialogue and the exchange of scientific ideas and is free of harassment and discrimination. All meeting participants are expected to behave professionally and treat others with respect, follow venue rules, and alert AUA staff or security of any dangerous situations or anyone in distress.

Reporting Harassment: It is the policy of the AUA that all meeting participants will enjoy an environment free from discrimination, harassment or retaliation. Harassing behavior by meeting participants will not be tolerated. If an individual experiences or witnesses harassment, he or she should contact Janet Skorepa, AUA EVP, at jskorepa@AUAnet.org or Maureen E. Cones, Esq., AUA General Counsel, at mcones@auanet.org or use a venue phone and ask for security if he or she feels unsafe. All complaints will be treated seriously and responded to promptly. 

The AUA reserves the right to take any action deemed necessary and appropriate, including refusing or revoking the registration of any individual, without refund, as long as such refusal is consistent with applicable law and AUA policy.

Disclaimer: The opinions and recommendations expressed by faculty, authors and other experts whose input is included in this program are their own and do not necessarily represent the viewpoint of the American Urological Association (AUA).

Consent to Use of Photographic Images: Registration and attendance at or participation in AUA meetings and other activities constitutes an agreement by the registrant to AUA's use and distribution (both now and in the future) of the registrant or attendee's image or voice in photographs, videotapes, electronic reproductions, and audiotapes of such events and activities.

Audio, Video, Photographic Equipment: The use of audio, video and other photographic recording equipment by attendees is prohibited inside AUA meeting rooms.

Reproduction Permission: Reproduction of written materials developed for this AUA course is prohibited without the written permission from individual authors and the AUA.

Special Assistance/Dietary Needs: The AUA complies with the Americans with Disabilities Act §12112(a). If any participant is in need of special assistance or has any dietary restrictions, a written request should be submitted at least one month in advance. For additional assistance with your request please call 1-800-908-9414.